Our publishing program is one way we share our take on issues important to clients. Bulletins and articles address time-sensitive updates, and larger publications speak to broader developments spanning industries and regions.
Indirect comparisons to an innovative drug’s data can trigger data protection provisions
COVID-19 triggers Canadian intellectual property deadline extensions until August 24, 2020
Schrems II decision invalidates EU-U.S. Privacy Shield and ushers in enhanced scrutiny of data transfers globally
Video: Canada First? A changing business sentiment
Video: what does a new ruling on Canada’s equivalent to patent term extension mean for the pharmaceutical industry?
Video: how are litigation strategies changing in the “new normal”?
Better late than never! Supreme Court ends “waiver of tort” controversy